Newly emerging data from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial: an investigator’s perspective.
Closing the gap: the EUROASPIRE study (European Action on Secondary Prevention by Intervention to Reduce Events) and what it can tell us for the treatment of diabetes patients.